Curis Announces Genentech's Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma
Links shared publicly online about this topic.
- 807total visits
Curis Announces Genentech's Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma
View full resource at medicalnewstoday.com
Tags: Cancer, Skin Cancer, Basal Cell Carcinoma, Drug, Genentech
Most Recently Shared on October 13, 2010 at 3:42 pm By:
Curis Announces Genentech's Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma: Curis, Inc... http://bit.ly/b5C68Y
Also Shared By:
Phase 2 trial of GDC-0449 for the treatment of operable basal cell carcinoma (BCC) - MPR
empr.com — “Curis, Inc. announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase 2 trial of GDC-0449 for patients with operable basal cell carcinoma (BCC).” View full resource at empr.com
Most Recently Shared on October 12, 2010 at 7:25 pm By:
MPR News: Phase 2 trial of GDC-0449 for the treatment of operable basal cell carcinoma (BCC): Curis, Inc. announce... http://bit.ly/9fcMD8
Genentech initiates GDC-0449 Phase II clinical trial in BCC patients
news-medical.net — “Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).” View full resource at news-medical.net
Most Recently Shared on October 11, 2010 at 3:50 pm By:
Lung Cancer News: Genentech initiates GDC-0449 Phase II clinical trial in BCC patients: Curis, Inc. a drug develop... http://bit.ly/dnRXw6
Genentech initiates GDC-0449 Phase II clinical trial in BCC patients
buzzup.com — “Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).” View full resource at buzzup.com
Most Recently Shared on October 11, 2010 at 3:09 pm By:
Ovarian Cancer News: Genentech initiates GDC-0449 Phase II clinical trial in BCC patients: Curis, Inc. a drug d... http://buzzup.com/1cd3s
Advertisement
MNT Clinical Trials
@mnt_clinical
Curis Announces Genentech's Initiation Of Phase II Trial For GDC-0449 In Operable Basal Cell Carcinoma http://mnt.to/3L54 #clinicaltrials
1 year ago...